Unlock Rapid Weight Loss with Semaglutide – Effortless and Effective!

The Agile Slims obesity telemedicine program is powered by the CareGLP™ platform by CareValidate Inc. CareGLP™ is a patient management platform that collaborates with independent physicians and practitioners providing services through the SOC2 and HIPAA Compliant Care360 platform. CareValidate Inc. does not directly offer medical or pharmacy services, and payment does not guarantee the prescription writing or dispensing process. Medical services are facilitated by independent providers. The information presented on this website is for informational purposes only and should not be considered a substitute for professional medical advice, diagnosis, or treatment. If you have questions or concerns about your health, please consult with your doctor.

Our goal is for you to have a comfortable and effective experience tailored to your desired results:
1) Complete the intake questionnaire. Your doctor will use this information to prepare for your consultation, and may order screening tests to determine if treatment is right for you.
2) Have a telehealth consultation with your doctor, who will check what treatment is needed and write a prescription if appropriate.
3) Your prescription will be delivered monthly via mail-order pharmacy.

Certainly. Only our medical team and prescribers have access to your medical data and order history. Please refer to our Privacy Policy for additional details.

If you meet the criteria for treatment, our medical professionals will provide you with a personal prescription. An existing prescription is not required to participate in the Agile Slims weight loss program.

The monthly cost starts $299 for compounded Semaglutide, which includes telehealth consultations with your doctor, a personalized weight loss plan, a monthly prescription for GLP-1 medication, shipping to your home, and email and phone support.

It’s important to contact your healthcare provider right away if you experience any symptoms such as a lump or swelling in your neck, hoarseness, difficulty in swallowing, or shortness of breath, as these may be indicators of thyroid cancer. Semaglutide should not be used if you or any family members have had medullary thyroid carcinoma (MTC), or if you have a condition known as Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). The effectiveness and safety of using semaglutide in combination with other weight loss products are yet to be confirmed. It is vital to share your full medical history with your healthcare provider. This includes informing them if you have had conditions like Type 1 or Type 2 diabetes, thyroid cancer, pancreatitis, kidney disease, diabetic retinopathy, depression, or any history of suicidal thoughts or behaviors.

Your delivery will be timely, following a thorough assessment by our medical team and the issuance of your prescription, typically within 5 to 7 days. Our process ensures a consistent supply of medication every month for your continued progress.

Weight reduction varies from person to person. Patients commonly report losing 5% to 10% of their starting weight, with longer treatment times tending toward more weight loss. For a 200 pound person, that would be 10 to 20 pounds.

Please refer to our educational videos on GLP1 Injection How-to for guidance on subcutaneous injection. If you encounter any issues or have questions, please consult your doctor through our support platform.

When a drug is in shortage, compounders can prepare a compounded version of that drug if they meet certain requirements in the Federal Food, Drug, and Cosmetic (FD&C) Act.

You can check for drug shortages on the FDA website.

Pharmacies in the CareGLP network comply strictly with all the regulatory standards established by:

• State boards of pharmacy, which regulate all 503A pharmacies
• FDA, which has oversight for the safety of all active pharmaceutical ingredients
• DEA, that oversees the controlled substances sometimes used in compounded preparations
• USP Convention, that issues practice standards ensuring quality and safety of medications and food
• USP General Chapter <795> provides guidelines for the prevention of contamination and potency variance, preparation process, beyond-use dates, and stability for non-sterile compounding

Pharmacies in the CareGLP network run quality assurance and quality control checks for every batch of compounded semaglutide prescribed to patients.

Some of these steps include but are not limited to:

• Reviewing and confirming the Active Pharmaceutical Ingredient (API) Certificate of Analysis for all semaglutide base lots, which are received from FDA-registered manufacturers;
• Storing the verified API frozen and sealed until use;
• Compounding with the API under aseptic processes to produce specific lots (vials);
• Holding the vials of compounded semaglutide in quarantine (representative samples are taken for testing);
• Using independent third-party laboratories to test the potency, sterility and endotoxicity of each lot of compounded semaglutide (among other criteria);
• Reviewing the results of these tests and, if satisfactory, releasing the validated vials from quarantine for dispensing;
• Assigning each compounded lot a unique lot number and BUD (Beyond Use Date), which is added to the container and is tracked electronically;
• Scanning the lot information on the product at the time of dispensing, which ties a particular lot number to the patient’s file.